“Life-saving” inappropriate implantable cardioverter-defibrillator shocks in a cancer patient

• Authors: Piotr Futyma , Marek Płoszczyca , Ryszard Głuszczyk , Jerzy Kuźniar
• Languages of publication: EN

Abstracts

EN

Impaired left ventricular ejection fraction (LVEF) in patients with cancer can disqualify them from targeted antineoplastic treatment. We present the case of 63-year-old male with gastric cancer treated palliatively, with concomitant dilated cardiomyopathy, atrial fibrillation (AF) and after implantation of a cardioverter-defibrillator (ICD), in whom inappropriate ICD discharges caused unexpected return of sinus rhythm and significant LVEF improvement, what subsequently led to reclassification to targeted chemotherapy. In conclusion, unexpected return of sinus rhythm in cancer patients with AF and reduced LVEF may lead to LVEF recovery and enable the use of antineoplastic treatment with improved prognosis.

Keywords

EN

implantable cardioverter-defibrillator; inappropriate shocks; unexpected return of sinus rhythm

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2016
• Volume: 6
• Issue: 3
• Pages: A118-121

Contributors

author

Piotr Futyma

• Department of Cardiology, St. Queen Jadwiga District Hospital No. 2, Rzeszow, Poland; Invasive Cardiology Department, St. Joseph’s Heart Centre, Rzeszow, Poland

author

Marek Płoszczyca

• Rev. Bronislaw Markiewicz Subcarpathian Oncology Centre, Brzozow, Poland

author

Ryszard Głuszczyk

• Department of Cardiology, St. Queen Jadwiga District Hospital No. 2, Rzeszow, Poland

author

Jerzy Kuźniar

• Department of Cardiology, St. Queen Jadwiga District Hospital No. 2, Rzeszow, Poland

References

• 1. van Rees JB, Borleffs CJ, de Bie MK et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011; 57(5): 556-562.
• 2. Powell BD, Saxon LA, Boehmer JP et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol 2013; 62(18): 1674- 1679.
• 3. Przybylski A, Sterliński M, Lewandowski M et al. Risk of thromboembolic complications in patients with permanent atrial fibrillation undergoing cardioverter-defibrillator implantation. Kardiol Pol 2002; 57(10): 306-312.
• 4. Lee DS, Krahn AD, Healey JS. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010; 55(8): 774-782.
• 5. Futyma M, Chudzik M, Wranicz JK et al. Atrial fibrillation in implantable cardioverter-defibrillator patients. Cardiol J 2005; 12(10): 706-712.
• 6. ESC Guidelines for the Management of Atrial Fibrillation of 2012. Kardiol Pol 2012; 70(4): 197-234.
• 7. Lelakowski J, Tomala I, Ćmiel A et al. Predictors of sinus rhythm return during defibrillation testing in patients with permanent atrial fibrillation undergoing implantation of a cardioverter-defibrillator. Kardiol Pol 2011; 69(1): 17-22.

• Document Type: article